Acellular Pertussis Completed Phase 4 Trials for Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)

IndicationStatusPhase
DBCOND0031302 (Acellular Pertussis)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00548171Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058Prevention
NCT02853929Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryPrevention
NCT00753649Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in InfantsPrevention
NCT02422264Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryPrevention
NCT00282295US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal DiseasePrevention
NCT01147900Evaluation of Boostrix™10 Years After Previous Booster VaccinationPrevention
NCT01362322Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old AdolescentsPrevention
NCT00635128Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio VaccinePrevention
NCT00610168Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.Prevention
NCT00611559Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old ChildrenPrevention
NCT01457547Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination CoursePrevention
NCT01294605Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)Prevention